Major Areas of Research
- Treatment monitoring strategies to optimize HIV care in resource limited settings
- Herpes virus co-infections among HIV positive individuals and their role in immune activation
- Epidemiology of transmitted and acquired HIV drug resistance in Uganda and South Africa
- Implementation of Combination HIV Prevention strategies to reduce HIV incidence in Uganda
Dr. Reynolds obtained his M.D. from McGill University in 1994 and went on to receive specialty certification in Internal Medicine, Medical Microbiology and Infectious Diseases. He completed his M.P.H. in 2002 at Johns Hopkins University while working on an HIV prevention collaboration in Pune, India. He is a senior clinician at NIAID and an associate professor of medicine and epidemiology at Johns Hopkins University. He has worked on collaborative research with colleagues in Uganda since 2003 where he oversees clinical and laboratory research activities for the NIAID International Centers for Excellence in Research (ICER) Program. In addition to providing scientific direction to the ICER program in Uganda, he continues to provide HIV care and treatment at both Rakai Health Sciences Program and at the Infectious Diseases Institute in Kampala.
Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, Kasule J, Serwadda D, Castelnuovo B, Hoog AV, Reynolds SJ. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017 Aug 22;17(1):582.
Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. J Int AIDS Soc. 2016 Jun 17;19(1):20773.
Reynolds SJ, Sempa JB, Kiragga AN, Newell K, Nakigozi G, Galiwango R, Gray R, Quinn TC, Serwadda D, Chang L. Is CD4 Monitoring Needed Among Ugandan Clients Achieving a Virologic and Immunologic Response to Treatment? AIDS Patient Care STDS. 2014 Nov;28(11):575-8.
Tobian AA, Grabowski MK, Serwadda D, Newell K, Ssebbowa P, Franco V, Nalugoda F, Wawer MJ, Gray RH, Quinn TC, Reynolds SJ; Rakai Health Sciences Program. Reactivation of herpes simplex virus type 2 after the initiation of antiretroviral therapy. J Infect Dis. 2013 Sep 1;208(5):839-46.
Reynolds SJ, Sendagire H, Newell K, Castelnuovo B, Nankya I, Kamya M, Quinn TC, Manabe YC, Kambugu A. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral therapy in Uganda. BMC Infectious Dis. 2012 Dec 27;12(381).
Reynolds SJ, Makumbi F, Newell N, Kiwanuka N, Ssebowa P, Mondo G, Boaz I, Wawer MJ, Gray RH, Serwadda D, Quinn TC. Daily acyclovir to prevent disease progression among HIV-1/HSV-2 co-infected individuals: a randomized, double-blinded placebo controlled trial in Rakai, Uganda. Lancet Infect Dis. 2012 Jun;12(6):441-8.